Chemours Co: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Feb 14, 2020 and accepted by EDGAR at Feb 14, 2020, 16:59 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $1.35bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2019-01-01 to 2019-12-31 | $5.53bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-10-01 to 2019-12-31 | $1.20bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 12 months2019-01-01 to 2019-12-31 | $4.46bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2019-01-01 to 2019-12-31 | $1.06bn | us-gaap:GrossProfit |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $80.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2019-01-01 to 2019-12-31 | $548.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 12 months2019-01-01 to 2019-12-31 | $208.0m | us-gaap:InterestExpense |
| Income tax | 12 months2019-01-01 to 2019-12-31 | −$72.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$317.0m | us-gaap:NetIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$52.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$1.94 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$0.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-10-01 to 2019-12-31 | −$1.94 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2019-01-01 to 2019-12-31 | −$0.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2019-01-01 to 2019-12-31 | 164,816,839 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | $650.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $481.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2019-01-01 to 2019-12-31 | $322.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-12-31 | $943.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $2.78bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $7.26bn | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $1.54bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $6.56bn | us-gaap:Liabilities |
| Long-term debt | At period end2019-12-31 | $4.03bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-12-31 | $134.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2019-12-31 | $689.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-004829. Last ingested by Listed: Nov 5, 2026, 19:57 ET. Listed shows no prices and gives no investment advice.